Director of Medical Excellence Mission Veterinary Partners Baton Rouge, Louisiana, United States
Disclosure(s):
Jenny Fisher, RVT, VTS (Oncology): No financial relationships to disclose
Presentation Description / Summary: This lecture-based presentation will discuss some of the new emerging oncology diagnostics and treatments. With multiple new early cancer detection tests on the market, this lecture will compare some of those with indications for use. With new diagnostics, come new treatments. This lecture will also review Laverdia-CA1, a new oral treatment for canine lymphoma and Stelfonta, an intra-tumoral treatment for mast cell tumors.
Learner Outcomes: Attendees will learn about new cancer detection tests, similarities and differences, and indications for use. Attendees will learn about new oral treatments for canine lymphoma. Attendees will learn about intra-tumor treatment of mast cell tumors.
Learning Objectives:
Evaluate Emerging Therapeutic Options: Learners will be able to describe the mechanisms of action, indications, and administration protocols for Laverdia-CA1 and Stelfonta in the treatment of canine lymphoma and mast cell tumors.
Differentiate Treatment Applications Across Practice Settings: Learners will compare the use of emerging oncology treatments in specialty versus general practice settings, identifying how these therapies expand treatment accessibility for a broader patient population.
Enhance Communication and Monitoring Strategies: Learners will develop strategies for discussing these new treatment options with pet owners, monitoring patient response, and determining when adjustments or referrals to specialty care may be needed.
